Clinical trial NCT02829255: Effect of High Altitude Exposure, Acclimatization and Re-exposure on Cerebral Autoregulation in Lowlanders
Official title: Effect of High Altitude Exposure, Acclimatization and Re-exposure on Cerebral Autoregulation in Lowlanders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Effect of High Altitude
Keywords: High altitude
Cerebral autoregulation
Transfer function analysis
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: University of Calgary
First posted: 2016-07-12
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Prospective interventional trial in lowlanders evaluating the effect of acute exposure, acclimatization and re-exposure to high altitude on cerebral autoregulation

Detailed description: Baseline measurements will be performed in Santiago de Chile, 520 m, over the course of 3 days. Participants will then travel by commercial airline (5 h flight) and by bus (3 h ride) to the ALMA base camp located at 2900 m near San Pedro de Atacama, northern Chile. Participants will stay there for the next 8 nights and they will be spend the days (6-8 h daily) at the telescope station at 5050 m while undergoing testing as described above at the first and the last day at 5050m. Daily transports from 2900 to 5050 m will be by car (1 h ride, one way). After the first 8 day altitude sojourn participants will return to the Santiago area (520 m) for a 6 day recovery period.

A second altitude sojourn with an identical schedule as the one described above and a final low altitude stay of 3 days will follow.

Eligibility criteria: Inclusion Criteria:

* Born, raised and currently living \<800m
* No overnight stay at altitudes \>1500 m 4 weeks before the study

Exclusion Criteria:

* Previous altitude intolerance to altitude \<3000 m
* Pregnancy
* Health impairment, which requires regular treatment

Primary outcomes:
measure: Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
timeFrame: day 1; day 2 first cycle
Secondary outcomes:
measure: Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
timeFrame: day 1; day 7 first cycle
measure: Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
timeFrame: day 2; day 7 second cycle
measure: Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
timeFrame: day 2 first cycle; day 2 second cycle
measure: Coherence between middle cerebral artery blood flow velocity and systemic blood pressure as measure of cerebral autoregulation.
timeFrame: day 7 first cycle; day 7 second cycle
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University of Zurich
Study officials:
affiliation: University of Zurich
name: Konrad E Bloch, MD
role: STUDY_CHAIR
References: